Thymosin Alpha-1: 28-Amino Acid Immunomodulator Research Overview

Thymosin Alpha-1 was first isolated in 1972 by Goldstein and colleagues from bovine thymic extracts. Subsequent characterization established its 28-amino acid sequence and its association with T-cell development biology.^[1]

The peptide became a research tool for immunology, particularly in T-cell signaling, after early studies showed effects on immature T-cell differentiation in vitro. More recent research has identified Toll-like receptor (TLR) pathway interactions, expanding the receptor pharmacology framework for the compound.^[2]

Thymosin Alpha-1 is studied as a research reference compound in preclinical immunology and signaling research. It has not been approved by the FDA for any human therapeutic or medical purpose in the United States, though clinical applications exist in some other jurisdictions.

Thymosin Alpha-1 structural features:

• Sequence: Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn (28 residues with N-terminal acetylation)

• Molecular formula: C₁₂₉H₂₁₅N₃₃O₅₅

• Molecular weight: approximately 3,108 Da

• N-terminal modification: acetylation (Ac-Ser)

• Net charge: highly acidic (numerous Asp, Glu residues)

The acidic character of Thymosin Alpha-1 (with numerous aspartate and glutamate residues) is unusual among signaling peptides and contributes to defined behavior in solution. The N-terminal acetylation is a natural post-translational modification preserved in synthetic preparations.^[3]

Tα1's research-characterized mechanisms span several signaling pathways.

Tα1 has been shown to engage Toll-like receptor 9 (TLR9) and TLR2 in immune cell preparations. TLR signaling drives downstream NF-κB activation and cytokine production, with these endpoints serving as quantitative measures in research preparations.^[4]

Tα1 effects on T-cell precursor maturation have been examined in thymic cell culture systems. Endpoints include surface marker expression panels (CD3, CD4, CD8) characteristic of progressive T-cell differentiation states.^[5]

Peripheral blood mononuclear cell (PBMC) preparations exposed to Tα1 have been examined for cytokine secretion profiles, with research interest in the balance of pro- and anti-inflammatory mediators.^[6]

Tα1 literature spans several immunology research domains.

Thymic cell culture and T-cell precursor preparations are common substrates. The compound is among the original tools that contributed to understanding of T-cell development biology in research labs.^[5]

Cell-based and animal model studies of antiviral immune response have included Tα1 in experimental arms, leveraging its immunomodulatory profile to probe pathway readouts.^[2]

Preclinical tumor models have examined Tα1 in combination with other immune-modulating compounds to study immune response to tumor antigens in animal systems.^[6]

Thymosin Alpha-1 is a relatively stable peptide for its size. The acidic character and lack of disulfide bonds simplify handling.

Lyophilized Tα1 is stored at minus 20 degrees Celsius for long-term preservation. Brief refrigerated storage at 4 degrees Celsius is acceptable.

Bacteriostatic water or sterile water are standard reconstitution solvents. The acidic peptide dissolves cleanly in aqueous solvents at neutral pH.

HPLC for purity, mass spectrometry for identity confirmation (matching the acetylated 28-residue mass), and endotoxin screening. Each batch of Instant Peptides Thymosin Alpha-1 ships with a full Certificate of Analysis.

Instant Peptides supplies Thymosin Alpha-1 as a synthetic lyophilized reference compound in 10mg vials. Material is supplied to qualified research professionals. Not for human or animal consumption.

View the product page for current pricing and the Certificate of Analysis for the active batch.